First Time Loading...

Eli Lilly and Co
NYSE:LLY

Watchlist Manager
Eli Lilly and Co Logo
Eli Lilly and Co
NYSE:LLY
Watchlist
Price: 762.7 USD -1.81%
Updated: May 2, 2024
Section:
 

Wall Street
Price Targets

LLY Price Targets Summary
Eli Lilly and Co

Wall Street analysts forecast LLY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LLY is 844.33 USD with a low forecast of 545.4 USD and a high forecast of 1 050 USD.

LLY Lowest Forecast
Wall Street Target
545.4 USD
28% Downside
LLY Average Forecast
Wall Street Target
844.33 USD
11% Upside
LLY Highest Forecast
Wall Street Target
1 050 USD
38% Upside
Lowest
Price Target
545.4 USD
28% Downside
Average
Price Target
844.33 USD
11% Upside
Highest
Price Target
1 050 USD
38% Upside

LLY Last Price Targets
Eli Lilly and Co

The latest public price target was made on May 1, 2024 by Evan Seigerman from BMO Capital , who expects LLY stock to rise by 31% over the next 12 months. You can read more about this price target by viewing the article on TheFly.

Analyst Price Target Date Article
Evan Seigerman
BMO Capital
1 001 USD
Upside 31%
1 day ago
May 1, 2024
Eli Lilly price target raised to $1,001 from $900 at BMO Capital
TheFly
Louise Chen
Cantor Fitzgerald
885 USD
Upside 16%
2 days ago
Apr 30, 2024
Eli Lilly (LLY) PT Raised to $885 at Cantor Fitzgerald
StreetInsider
Evan David Seigerman
BMO Capital
900 USD
Upside 18%
2 weeks ago
Apr 18, 2024
BMO Capital Reiterates Outperform Rating on Eli Lilly (LLY)
StreetInsider
James Shin
Deutsche Bank
535 USD
Downside 30%
2 months ago
Feb 6, 2024
Eli Lilly Likely To Report Higher Q4 Earnings; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Benzinga
Andrew Baum
Citigroup
675 USD
Downside 11%
4 months ago
Dec 28, 2023
Eli Lilly, Johnson & Johnson And Other Health Care Stocks From Wall Street's Most Accurate Analysts
Benzinga
David Phung
Morgan Stanley
673 USD
Downside 12%
6 months ago
Oct 11, 2023
What's Going On With Eli Lilly Stock Wednesday?
Benzinga
Terence Flynn
Morgan Stanley
617 USD
Downside 19%
8 months ago
Aug 9, 2023
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: 'Beyond Mounjaro, Alzheimer's Franchise Remains A Key Pillar To Future Growth'
Benzinga
Louise Chen
Cantor Fitzgerald
630 USD
Downside 17%
8 months ago
Aug 9, 2023
Eli Lilly Analysts Bump Up Forecasts On Q2 Print: 'Beyond Mounjaro, Alzheimer's Franchise Remains A Key Pillar To Future Growth'
Benzinga
Unknown Analyst
Morgan Stanley
455 USD
Downside 40%
1 year ago
Feb 3, 2023
Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $455
Benzinga
Unknown Analyst
Wells Fargo
360 USD
Downside 53%
1 year ago
Feb 3, 2023
Wells Fargo Maintains Equal-Weight on Eli Lilly, Lowers Price Target to $360
Benzinga
Show More Price Targets
Show Less Price Targets
Evan Seigerman
BMO Capital
Price Target 1 001 USD
Upside/Downside 31%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 885 USD
Upside/Downside 16%
View Source
Evan David Seigerman
BMO Capital
Price Target 900 USD
Upside/Downside 18%
View Source
James Shin
Deutsche Bank
Price Target 535 USD
Upside/Downside 30%
View Source
Andrew Baum
Citigroup
Price Target 675 USD
Upside/Downside 11%
View Source
David Phung
Morgan Stanley
Price Target 673 USD
Upside/Downside 12%
View Source
Terence Flynn
Morgan Stanley
Price Target 617 USD
Upside/Downside 19%
View Source
Louise Chen
Cantor Fitzgerald
Price Target 630 USD
Upside/Downside 17%
View Source
Unknown Analyst
Morgan Stanley
Price Target 455 USD
Upside/Downside 40%
View Source
Unknown Analyst
Wells Fargo
Price Target 360 USD
Upside/Downside 53%
View Source
Show More Price Targets
Show Less Price Targets
Eli Lilly and Co Competitors:
Price Targets
4503
Astellas Pharma Inc
33% Upside
N
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
50% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
43% Upside
1760
Panion & BF Biotech Inc
13% Upside
4503
Astellas Pharma Inc
33% Upside
N
603707
Nanjing King-friend Biochemical Pharmaceutical Co Ltd
50% Upside
300401
Zhejiang Garden Bio-chemical High-tech Co Ltd
43% Upside
1760
Panion & BF Biotech Inc
13% Upside
G
GTII
Green Thumb Industries Inc
33% Upside
CGTX
Cognition Therapeutics Inc
305% Upside
COPN
Cosmo Pharmaceuticals NV
26% Upside
002349
Jinghua Pharmaceutical Group Co Ltd
293% Upside

Revenue
Forecast

Revenue Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's revenue is 7%. The projected CAGR for the next 3 years is 22%.

7%
Past Growth
22%
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's operating income is 14%. The projected CAGR for the next 3 years is 35%.

14%
Past Growth
35%
Estimated Growth
Estimates Accuracy
-12%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Eli Lilly and Co

For the last 8 years the compound annual growth rate for Eli Lilly and Co's net income is 10%. The projected CAGR for the next 3 years is 65%.

10%
Past Growth
65%
Estimated Growth
Estimates Accuracy
-17%
Average Miss
What are analyst estimates?

See Also

Summary
LLY intrinsic value, competitors valuation, and company profile.
DCF Valuation
LLY stock valuation using Discount Cash Flow valuation method.
Relative Valuation
LLY stock valuation using valuation multiples.
Wall Street Estimates
LLY price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
LLY stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is LLY's stock price target?
Price Target
844.33 USD

According to Wall Street analysts, the average 1-year price target for LLY is 844.33 USD with a low forecast of 545.4 USD and a high forecast of 1 050 USD.

What is Eli Lilly and Co's Revenue forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's revenue is 7%. The projected CAGR for the next 3 years is 22%.

What is Eli Lilly and Co's Operating Income forecast?
Projected CAGR
35%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's operating income is 14%. The projected CAGR for the next 3 years is 35%.

What is Eli Lilly and Co's Net Income forecast?
Projected CAGR
65%

For the last 8 years the compound annual growth rate for Eli Lilly and Co's net income is 10%. The projected CAGR for the next 3 years is 65%.

ALPHA SPREAD
Join more than 133,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.